CHUGAI PHARMACEUTICAL CO., LTD.
Information Meeting on Vabysmo
June 24, 2022
Event Summary
[Company Name] | CHUGAI PHARMACEUTICAL CO., LTD. | |
[Company ID] | 4519-QCODE | |
[Event Language] | JPN | |
[Event Type] | Investor Conference | |
[Event Name] | Information Meeting on Vabysmo | |
[Fiscal Period] | ||
[Date] | June 24, 2022 | |
[Number of Pages] | 56 | |
[Time] | 10:30 - 12:04 | |
(Total: 94 minutes, Presentation: 60 minutes, Q&A: 34 minutes) | ||
[Venue] | Webcast | |
[Venue Size] | ||
[Participants] | ||
[Number of Speakers] | 3 | |
Masashi Kishida | Vabysmo Lifecyle Leader | |
Tomohiro Iida | Professor and Chairman, Department of | |
Ophthalmology, Tokyo Women's Medical | ||
University | ||
Toshiya Sasai | Head of Corporate Communications | |
Department | ||
[Analyst Names]* | Fumiyoshi Sakai | Credit Suisse Securities (Japan) Limited |
Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. | |
Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. | |
Shinichiro Muraoka | Morgan Stanley MUFG Securities Co., Ltd. |
*Analysts that SCRIPTS Asia was able to identify from the audio who spoke during Q&A.
Support | |||
Japan | 050.5212.7790 | North America | 1.800.674.8375 |
Tollfree | 0120.966.744 | Email Support | support@scriptsasia.com |
1
Presentation
Sasai: Hello. Thank you very much for taking time out of your busy schedule today to attend the product presentation of our new ophthalmologic treatment, Vabysmo.
I'm Sasai of the Corporate Communications Department, and I'll be moderating today's session. Thank you.
To prevent the spread of novel coronavirus infection, today's session will be conducted as a combination of an on-site lecture and a Zoom webinar. The agenda for today's meeting can be found on the web page and on page two of the presentation material. Please follow the contents of this page.
Today, we have invited as a special lecturer, Dr. Tomohiro Iida, Professor and Chairman, Department of Ophthalmology, Tokyo Women's Medical University. Dr. Iida's biography, along with today's presentation materials, have been distributed in advance. I would like to skip the biography in this presentation. We kindly ask for your understanding. Questions will be taken collectively after all presentations have been completed. The Q&A session is scheduled to last about 30 minutes.
I would now like to turn the session over to Dr. Kishida, Vabysmo Lifecycle Leader.
Kishida: My name is Kishida. I'm the Vabysmo Lifecycle Leader of CHUGAI PHARMACEUTICAL CO., LTD. Thank you for attending today's presentation.
First, let me give you a product overview of the Vabysmo Intravitreal Injection solution. Here is a slide showing the features of Vabysmo. Vabysmo is the first bispecific antibody in the ophthalmologic field that specifically binds to vascular endothelial growth factor A, a molecule called VEGF-A, and Ang-2.
The English spelling of Vabysmo is thus: V stands for VEGF-A, A for Ang-2, BYS for Bispecific, and MO for Molecule. Vabysmo binds not only VEGF-A but also Ang-2, two cytokines, at the same time, and is expected
Support | |||
Japan | 050.5212.7790 | North America | 1.800.674.8375 |
Tollfree | 0120.966.744 | Email Support | support@scriptsasia.com |
2
to improve vascular stability, increase vascular permeability, and inhibit angiogenesis. The Fc domain, which is the area connecting the two Fabs, has been modified to reduce systemic exposure and inflammation induction.
Next, I will briefly discuss the mechanisms of vascular stabilization and destabilization.
VEGF-A is inflammation and angiogenesis, the molecule called Ang-1 is vascular stabilizing, a good thing, and Ang-2 is vascular destabilizing a bad factor. In normal vascular endothelial cells, Ang-1 binds to Tie-2 receptors and generates signals that stabilize the pericytes lining the vessels, thereby maintaining and stabilizing vascular homeostasis.
It is known that Ang-2 and VEGF-A are simultaneously elevated in the eyes of patients with age-related macular degeneration and diabetic macular edema due to destabilization. Ang-2 acts as an antagonist to Ang- 1, removing Ang-1 from the Tie-2 receptor and stopping this stabilizing signal by binding Ang-2 to the receptor.
At the same time, a molecule called VEGF-A binds to VEGF receptor 2 and generates signaling, which in total increases inflammation, permeability, and angiogenesis. The patient's vision is then said to be reduced by the occurrence of destabilized blood vessels due to leakage of plasma components, pericyte detachment, and angiogenesis.
Support | |||
Japan | 050.5212.7790 | North America | 1.800.674.8375 |
Tollfree | 0120.966.744 | Email Support | support@scriptsasia.com |
3
Vabysmo can inhibit VEGF-A and Ang-2 simultaneously with this single molecule. By simultaneously trapping increased Ang-2 and VEGF-A in the patient's eye, the Ang-2 inhibitory effect works primarily to suppress vascular destabilization due to pericyte loss, increased vascular permeability, and increased VEGF-A sensitivity. At the same time, by inhibiting VEGF-A, it is believed to suppress increased vascular permeability, angiogenesis, and inflammation, thereby contributing to the improvement of patients' visual acuity.
Support | |||
Japan | 050.5212.7790 | North America | 1.800.674.8375 |
Tollfree | 0120.966.744 | Email Support | support@scriptsasia.com |
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 27 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 June 2022 09:45:12 UTC.